SII’s cervical cancer vaccine: SEC to review HPV jab trial data today

The subject expert committee (SEC) under the drug regulator will review the trial data of the vaccine that has been developed by Serum Institute of India (SII).

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/jQDLiqI
via IFTTT